The upcoming drugs CagriSema and retatrutide target multiple gut hormones and could cause twice as much weight loss than ...

The prevalence of obesity is high in the United States and is expected to continue increasing to 46.9 percent of the adult population by 2035.

Even now, as the crisis worsens with the new definition of obesity, the reflex is to reach for prescription drugs to “solve” ...

GLP-1 drugs like Ozempic and Wegovy are often portrayed as sudden breakthroughs, but their roots extend back more than a ...

Doctors, patients and researchers are at the very beginning of understanding how the new class of obesity drugs interact with eating disorders.

Researchers have quantified the role of obesity in common long-term conditions, showing for the first time the effect of ...

Clinical obesity occurs more frequently in certain sociodemographic groups and is linked to increased risks for stroke, heart failure, and heart attack.

New obesity standards focus on belly fat and body composition, affecting men and Asian individuals most dramatically ...

Using data culled from nearly 11 million people, the researchers found that just over 19% were obese in 1990, compared to ...

The number of Americans living with obesity is expected to rise by 19 million and affect nearly 126 million people by 2035, ...

Some people with obesity have a distinct oral microbiome signature – a discovery that could lead to a way to spot the condition early and potentially prevent it. “The oral microbiome is the second ...

If you're one of tens of millions of Americans on a GLP-1 weight loss drug, you know how effective they can be. Now, an even more powerful drug is on the horizon from pharmaceutical company Eli Lilly.